Only 4 % of the solid tumor models showed an objective response to the six VEGF-pathway targeted agents, while 41 % of the models showed the 2-fold or greater slowing of tumor growth required for the PD2 response category (Table 3). The gene discussed is VEGFA; the disease is neoplasm.